1. Home
  2. MEIP vs SWAG Comparison

MEIP vs SWAG Comparison

Compare MEIP & SWAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • SWAG
  • Stock Information
  • Founded
  • MEIP 2000
  • SWAG 1994
  • Country
  • MEIP United States
  • SWAG United States
  • Employees
  • MEIP N/A
  • SWAG N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • SWAG Advertising
  • Sector
  • MEIP Health Care
  • SWAG Consumer Discretionary
  • Exchange
  • MEIP Nasdaq
  • SWAG Nasdaq
  • Market Cap
  • MEIP 16.3M
  • SWAG 14.7M
  • IPO Year
  • MEIP 2003
  • SWAG 2021
  • Fundamental
  • Price
  • MEIP $2.87
  • SWAG $0.83
  • Analyst Decision
  • MEIP Hold
  • SWAG
  • Analyst Count
  • MEIP 2
  • SWAG 0
  • Target Price
  • MEIP $7.00
  • SWAG N/A
  • AVG Volume (30 Days)
  • MEIP 36.2K
  • SWAG 68.4K
  • Earning Date
  • MEIP 02-11-2025
  • SWAG 01-28-2025
  • Dividend Yield
  • MEIP N/A
  • SWAG N/A
  • EPS Growth
  • MEIP N/A
  • SWAG N/A
  • EPS
  • MEIP N/A
  • SWAG 0.00
  • Revenue
  • MEIP N/A
  • SWAG $75,893,871.00
  • Revenue This Year
  • MEIP N/A
  • SWAG $11.55
  • Revenue Next Year
  • MEIP $300.00
  • SWAG N/A
  • P/E Ratio
  • MEIP N/A
  • SWAG $440.42
  • Revenue Growth
  • MEIP 33.76
  • SWAG 28.74
  • 52 Week Low
  • MEIP $2.30
  • SWAG $0.73
  • 52 Week High
  • MEIP $4.97
  • SWAG $1.69
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 66.22
  • SWAG 41.80
  • Support Level
  • MEIP $2.56
  • SWAG $0.75
  • Resistance Level
  • MEIP $2.78
  • SWAG $1.01
  • Average True Range (ATR)
  • MEIP 0.15
  • SWAG 0.07
  • MACD
  • MEIP 0.04
  • SWAG -0.00
  • Stochastic Oscillator
  • MEIP 100.00
  • SWAG 45.07

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About SWAG Stran & Company Inc.

Stran & Co Inc is an outsourced marketing solutions provider, working closely with customers to develop sophisticated marketing programs that leverage promotional products and loyalty incentive expertise. In addition to selling branded products, It offer its clients with custom sourcing capabilities which is a flexible and customizable e-commerce solution for promoting branded merchandise and other promotional products, managing promotional loyalty and incentives, print collateral, and event assets, order and inventory management, and designing and hosting online retail popup shops. The company purchases products and branding through various third-party manufacturers and decorators and resells the finished goods to customers.

Share on Social Networks: